Human polyomavirus 9 infection in kidney transplant patients by Meijden, E. van der et al.
Several human polyomaviruses of unknown preva-
lence and pathogenicity have been identified, including hu-
man polyomavirus 9 (HPyV9). To determine rates of HPyV9 
infection among immunosuppressed patients, we screened 
serum samples from 101 kidney transplant patients in the 
Netherlands for HPyV9 DNA and seroreactivity. A total of 
21 patients had positive results for HPyV9 DNA; positiv-
ity rates peaked at 3 months after transplantation, but the 
highest viral loads were measured just after transplantation. 
During 18 months of follow-up, HPyV9 seroprevalence in-
creased from 33% to 46% among transplant patients; sero-
prevalence remained stable at ≈30% in a control group of 
healthy blood donors in whom no HPyV9 DNA was detect-
ed. Further analysis revealed an association between de-
tection of HPyV9 and detection of BK polyomavirus but not 
of cytomegalovirus. Our data indicate that HPyV9 infection 
is frequent in kidney transplant patients, but the nature of 
infection—endogenous or donor-derived—and pathogenic 
potential of this virus remain unknown.
The Polyomaviridae constitute a family of small DNA viruses that infect a variety of hosts. BK polyomavirus 
(BKPyV) and JC polyomavirus (JCPyV), discovered in 
1971 (1,2), are well-known examples of human polyoma-
viruses (HPyVs) that cause severe disease in immunocom-
promised patients. Serologic data have revealed that most 
polyomaviruses are ubiquitous (3–6). In case of JCPyV 
and BKPyV, primary infection occurs early in life, with-
out apparent symptoms, and persists throughout life as la-
tent infection in the kidneys, accompanied by occasional 
virus shedding in urine (7). When immunity is decreased, 
these viruses can reactivate with detectable viremia and 
manifestation of disease, which poses a threat to, among 
others, patients who receive solid-organ transplants. 
For kidney transplant patients, BKPyV infection is con-
sidered the most common viral complication and causes 
nephropathy and graft loss in 1%–10% of cases if left un-
treated (8). It is not known what determines the severity 
of BKPyV infection and whether co-infection is involved 
in the pathogenesis. 
Since 2007, at least 10 novel HPyVs have been discov-
ered (9–20); of these, Merkel cell polyomavirus (MCPyV) 
and trichodysplasia spinulosa–associated polyomavirus 
(TSPyV) have been shown to be associated with disease 
(11,19,21,22). Human polyomavirus 9 (HPyV9), so far 
without a disease association, was identified in 2011 from a 
serum sample from a kidney transplant patient (17). Over-
all seroprevalence of HPyV9 has been determined to be 
25% to 50% (23–26).
Because HPyV9 was originally isolated from a kid-
ney transplant recipient (17), we aimed to systematically 
study the presence of HPyV9 infection in kidney transplant 
patients and investigate a possible association with the 
known nephropathogenic BKPyV. We analyzed a cohort 
of 101 transplant patients who received either a kidney 
transplant or a simultaneous kidney–pancreas transplant 
for the appearance of markers for HPyV9 infection dur-
ing the 18 months after transplantation. We assessed the 
presence of HPyV9 DNA and IgG seroresponses in serum 
samples. The HPyV9 findings in the transplant cohort were 
compared with those obtained for an age- and sex-matched 
cohort of healthy blood donors. Co-infection with BKPyV 
was investigated by comparing observed HPyV9 and BK-
PyV viremia levels in the transplant cohort. For compara-
tive purposes, we also tested for cytomegalovirus (CMV), 
which, like polyomaviruses, frequently reactivates during 
immunosuppressive drug use after transplantation.
Materials and Methods
Study Population
The cohort study consisted of 101 patients who re-
ceived kidney (n = 83) or kidney–pancreas (n = 18) trans-
plants during 2002–2004 at Leiden University Medical 
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Center (LUMC), Leiden, the Netherlands (Table 1). This 
study population is part of a larger prospective European 
multicenter study designed to investigate the role of human 
papillomavirus infection in the development of skin cancer 
in solid-organ transplant patients (27). The study adhered 
to the Declaration of Helsinki Principles, and the medi-
cal ethical committee of the LUMC approved of the study 
design (Medical Ethical Committee no. P02.111). Partici-
pants gave written informed consent. 
All patients received induction with interleukin-2 re-
ceptor blocker daclizumab (100 mg/d) on the day of trans-
plantation and 10 days after transplantation or basiliximab 
(40 mg at days 0 and 4), followed by triple therapy with 
prednisone, tacrolimus, or cyclosporine and mycopheno-
late mofetil. For kidney transplant patients, the dose of the 
calcineurin inhibitor (tacrolimus or cyclosporine) was ta-
pered at 6 weeks after transplantation, whereas for kidney–
pancreas transplant patients, the calcineurin inhibitor was 
reduced at 3 months after transplantation.
The time points of serum sample collection and the 
number of samples collected per time point are summarized 
in Table 2 and shown in relation to the date of transplanta-
tion. The baseline samples were obtained in the days im-
mediately after transplantation (time point 0, T0). To col-
lect the subsequent samples, patients were asked to visit the 
LUMC outpatient clinic for follow-up sample collection at 
the preferred time points of 3, 6, 9, 12, and 18 months after 
transplantation (T3–T18). A total of 58 patients provided a 
sample at all 6 time points: 31, 6, 4, and 2 patients provided 
5, 4, 3, or 1 samples, respectively.
Stored pretransplantation serum samples, if available, 
were retrieved and tested for HPyV9 DNA (n = 65; Table 
2) and antibodies (n = 45, 40 of which were also included 
in pretransplantation DNA testing). The average dates of 
obtaining samples for DNA and antibody testing were 8 
and 2 days before transplantation, respectively.
To obtain a healthy control population, we analyzed 
anonymized samples from 87 random unpaid blood donors 
(Table 2). For each donor, 2 follow-up serum samples were 
studied, collected 1 year apart (T0 and T12). The donors 
were matched for age and sex with the transplant patient 
study population (Table 1).
Viral DNA Detection and Quantification
Total nucleic acids were extracted from 200 µL serum 
by using the MagNA Pure LC Total Nucleic Acid Isolation 
Kit–High Performance and MagNA Pure LC Instrument 
(Roche Diagnostics, Indianapolis, IN, USA). To monitor 
the quality of DNA extraction and potential PCR inhibi-
tion, we added low concentrations of phocine herpesvirus 
(28) to the lysis buffer. DNA was eluted in a final volume 
of 100 mL elution buffer, of which 10 mL was used as in-
put for real-time quantitative PCR (qPCR).
Primers and Taqman probes were designed by using 
Beacon Designer software (Premier Biosoft, Palo Alto, 
CA, USA). For HPyV9, we used the following prim-
ers and probe, located in the viral protein (VP) 1 gene 
amplifying a product of 109 nt: sense primer 5′- CCT-
GTAAGCTCTCTCCTTA-3′, antisense primer 5′- CCT-
GATAAATTCTGACTTCTTC-3′, and probe FAM-5′- 
CTTGTTCTCTGGTCTTATGCCTCA-3′-BHQ-1. For 
BKPyV, we used the following primers and probe, located 
in the VP1 gene amplifying a product of 90 nt: sense prim-




The BKPyV qPCR and phocine herpesvirus PCR 
were duplexed for DNA quality and potential PCR inhibi-
tion monitoring. Furthermore, the BKPyV qPCR was val-
idated to detect BKPyV genotypes I–IV. qPCR reactions 
were performed in a total volume of 50 μL, containing 25 
μL HotStart Taq mastermix (QIAGEN, Hilden, Germany), 
0.5 µmol/L of each primer, 0.35 µmol/L BKPyV probe or 
0.4 µmol/L HPyV9 probe, and 3.5 mmol/L MgCl2. Re-
actions were performed by using a CFX96 real-time de-
tection system (Bio-Rad, Hercules, CA, USA) with the 
following cycle conditions: 15 min at 95°C followed by 
45 cycles of amplification (30 s at 95°C; 30 s at 60°C for 
HPyV9 qPCR and 55°C for BKPyV qPCR; 30 s at 72°C). 
For quantification, a standard of pGEX 5×3 HPyV9 VP1 
plasmid (Genscript, Piscataway, NJ, USA) and of a quan-
tified BKPyV-positive urine sample were used. Analyti-
cal sensitivity of the HPyV9 and BKPyV qPCRs was ≈10 
copies/mL. CMV load was measured as described (29) 
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Table 1. Characteristics of patients and controls for study of human polyomavirus 9 prevalence among kidney transplant patients, the 
Netherlands* 
Characteristic 
Transplant patient type 
Blood donors All Kidney Kidney–pancreas p value 
Patients and controls 101 83 (82) 18 (18)  87 
Mean age, y (range) 47 (21–74) 48 (21–74) 43 (30–54) 0.129† 52 (29–68) 
Sex      
 F 34 (34) 27 (33) 7 (39) 0.605‡ 31 (36) 
 M 67 (66) 56 (67) 11(61)  56 (64) 
*Values are no. (%) except as indicated. 
†Comparison of kidney and kidney–pancreas patient groups; Student t test. 
‡Comparison of kidney and kidney–pancreas patient groups; 2 test. 
 
HPyV9 in Kidney Transplant Patients
with minor adjustments: 0.5 µmol/L of each primer, 0.2 
µmol/L probe, and HotStart Taq mastermix (QIAGEN) 
was used with the following cycle conditions: 15 min at 
95°C, followed by 45 cycles of amplification (5 s at 95°C, 
15 s at 63°C, 15 s at 72°C). Analytical sensitivity of the 
CMV qPCR was ≈100 copies/mL. On each plate, 3 nega-
tive controls were included; these controls tested negative 
in all PCR assays. PCR results with a cycle threshold ≥40 
were considered negative.
HPyV9 DNA Sequencing
HPyV9-positive PCR samples were confirmed by se-
quencing. PCR products were cloned by using the TOPO 
TA Cloning Kit (Invitrogen, Carlsbad, CA, USA) accord-
ing to the manufacturer’s instructions and subsequently se-
quenced. Sequence reactions were performed by using the 
BigDye Terminator Kit (Applied Biosystems, Foster City, 
CA, USA) and analyzed on an ABI Prism 3130 Genetic 
Analyzer (Applied Biosystems).
HPyV9 Serologic Testing
To detect IgG seroresponses against the major capsid 
protein VP1 of HPyV9, we performed an antibody-binding 
assay using Luminex xMAP technology (30), as described 
(26). Briefly, the assay is based on cross-linking of glutathi-
one to casein, which is subsequently coupled to fluorescent 
polystyrene beads (Bio-Rad). Glutathione S-transferase 
HPyV9 VP1 fusion protein was affinity purified on the beads. 
Serum samples were tested in a 1:100 dilution, and VP1-
bound antibodies were detected with biotinylated goat anti-
human IgG (H+L; Jackson Immuno Research, West Grove, 
PA, USA), followed by streptavidine-R-phycoerythrin 
(Invitrogen). Finally, the beads and the phycoerythrin sig-
nal were analyzed in a Bio-Plex 100 Analyzer (Bio-Rad), 
which gave results in median fluorescent intensity (MFI). 
For background correction, MFI values of glutathione S-
transferase alone were subtracted to obtain HPyV9 VP1–
specific signals. Quality control was performed on each 
plate with a serum pool consisting of 4 serum samples that 
had been analyzed in a 1:4 serial dilution, starting with a 
dilution of 1:100 up to 1:409,600. Little interplate variance 
was observed.
Cutoff Value Determination
The cutoff value of the antibody-binding assay was de-
fined on the basis of a group of healthy children 0.5–2 years 
of age and determined as described by van der Meijden et 
al. (26). The transplant patients and the healthy blood do-
nors were analyzed in 2 independent antibody-binding as-
says. HPyV9 cutoff values of 252 MFI and 311 MFI were 
determined for the transplant patient group and the blood 
donor group, respectively.
Statistical Analyses
Differences between groups in terms of HPyV9 DNA 
or seroprevalence were assessed by using the Pearson χ2 
or Fisher exact test, as appropriate for population size. 
Independent Student t tests or analyses of variance were 
used for comparisons of mean values between groups. 
Occurrence of HPyV9 viremia at transplantation was cal-
culated by using the Kaplan-Meier method, with the time 
from transplantation to the next detected HPyV9 DNA as 
the outcome variable for HPyV9-seronegative and -posi-
tive patients at baseline (T0). HPyV9 seroconversion at 
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Table 2. Detection of human polyomavirus 9 DNA and viral loads in kidney transplant patients and blood donors, the Netherlands* 
Population 
Mean time after transplantation or 
first sample collection, mo (range) 
No. 
samples 
No. (%) HPyV9 
DNA positive 
Mean viral load, 
copies/mL (range) 
Transplantation patients  101 21 (20.8)† 157 (25–530)‡ 
 Transplant type     
  Kidney  83 17 (20.5)† 135 (25–530)‡ 
  Kidney and pancreas  18 4 (22.2)† 250 (89–472)‡ 
 No. serum samples  541 27 (5.0) 137 (25–530) 
 Mo after transplant     
  Pretransplant§ –0.3 (–1.4 to 0) 65 0 NA 
  0 0.4 (0.1–1.2) 99 3 (3.0) 203 (141–265) 
  3 3.5 (2.3–5.5) 98 7 (7.1) 172 (52–530) 
  6 6.5 (5.5–9.6) 97 6 (6.2) 141 (25–472) 
  9 9.6 (7.6–12.6) 80 5 (6.3) 125 (45–213) 
  12 12.6 (9.3–16.0) 87 4 (4.6) 80 (66–92) 
  18 18.2 (16.0–21.3) 80 2 (2.5) 51 (38–63) 
Blood donors  87 0 NA 
 No. serum samples  174 0 NA 
 Mo after first sample collection     
  0 0 87 0 NA 
  12 13.4 (9.9–18.1) 87 0 NA 
*NA, not applicable. 
†Patients HPyV9 positive in the follow-up period after transplant. 
‡Mean load of HPyV9 DNA–positive patients based on the first positive sample per patient. 




transplantation was calculated by using the Kaplan-Meier 
method with the time from transplantation to the next se-
ropositive sample as the outcome variable for HPyV9 vire-
mic and nonviremic patients during follow-up. For all tests, 
2-tailed p values ≤0.05 were considered significant. The 
statistical analyses in this study were performed by using 
SPSS 20 (IBM, Armonk, NY, USA) and Prism 3 statistical 
software (GraphPad Software Inc., San Diego, CA, USA).
Results
HPyV9 Viremia in Kidney Transplant Patients
To determine HPyV9 viremia in the transplant patients, 
we assessed the presence of HPyV9 DNA in the complete 
sample set. During the 18 months after transplantation, 
HPyV9 DNA was detected at some point in 21 (20.8%) of 
the 101 patients (Table 2). No significant difference in the 
detection of HPyV9 DNA was observed between kidney 
and kidney–pancreas transplant patients (20.5% vs. 22.2%, 
respectively). For 3 (3.0%) patients, results were positive 
for consecutive serum samples; persistent HPyV9 DNA 
detection throughout the follow-up period was observed 
for 1 patient. Shortly after transplantation (T0, on average 
11 days after transplantation), HPyV9 DNA was detected 
in 3.0% of patients. Detection of HPyV9 DNA peaked 3 
months after transplantation (7.1% positivity) and gradu-
ally decreased to 2.5% 18 months after transplantation 
(Figure 1; Table 2).
Lack of HPyV9 Viremia before Transplantation  
and in Controls
To explore the possibility that the observed viremia was 
not related to the transplant and immunosuppression but to 
the underlying cause of the kidney disease (e.g., diabetes), 
we retrieved and analyzed pretransplantation serum sam-
ples for 65 (64%) of the 101 transplant patients. In addition, 
the group of 87 healthy blood donors was analyzed for the 
presence of HPyV9 DNA. No DNA was detected in either 
of these sample sets. To confirm the HPyV9-specificity of 
our PCR findings in the transplant patients, we cloned and 
sequenced 13 of the 27 HPyV9-positive PCR products, 109 
nt in length. The results revealed a complete match with 
the described HPyV9 DNA sequence in GenBank (acces-
sion no. NC_015150) for 12 of 13 samples. In 1 sample, a 
single nonsynonymous nucleotide mismatch was observed 
(A→G at position 2403), resulting in an I321V amino acid 
mutation in the VP1 capsid protein.
Peak of HPyV9 Viral Load Immediately  
after Transplantation
The mean HPyV9 DNA load after transplantation was 
137 copies/mL (range 25–530 copies/mL). On average, the 
highest viral loads were observed immediately after trans-
plantation (Figure 1). The kidney–pancreas transplant pa-
tients tended to show higher HPyV9 DNA loads than did 
kidney transplant patients (mean values of 250 and 135 
copies/mL, respectively; Table 2), but this difference was 
not statistically significant (p = 0.123 by Student t test).
HPyV9 Seroreactivity Increase in Transplant Patients 
but Not in Controls
HPyV9 seroresponses were analyzed for the complete 
sample set. At baseline, just after transplantation (T0), 33% 
of transplant patients were HPyV9 seropositive. This per-
centage corresponds to the percentages that we measured 
in healthy blood donors (29%) and in 45 pretransplantation 
serum samples (31%). However, at 1 year after transplan-
tation (T12), the seropositivity rate for transplant patients 
rose to 46%. This percentage differed significantly from 
the rate measured for blood donors, which remained stable 
at ≈30% during 1 year of follow-up (p = 0.029 by χ2 test) 
(Figure 2, panel A). In total, 15 (15%) of 101 transplant 
patients seroconverted during follow-up (online Technical 
Appendix Figure 1, wwwnc.cdc.gov/EID/article/20/6/14-
0055-Techapp1.pdf); these patients represent 23% (15/66) 
of the patients who were seronegative at baseline. 
The intensity of measured HPyV9 serologic respons-
es also increased after transplantation, whereas HPyV9 
seroreactivity in blood donors was lower at baseline and 
remained low within a comparable follow-up period of 1 
year (Figure 2, panel B). Mean HPyV9 seroreactivity in 
the 1-year follow-up samples was significantly higher for 
the transplant group than for blood donors (p = 0.008 by 
Student t test). Further analysis of the transplant population 
revealed that kidney–pancreas transplant patients in partic-
ular were responsible for the observed increase in HPyV9 
seroreactivity after transplantation (Figure 2, panels C, D). 
Kidney–pancreas transplant patients had lower mean se-
roreactivity at baseline than did kidney transplant patients 
(Figure 2, panel D); the relative increase of seroreactivity 
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Figure 1. Human polyomavirus 9 (HPyV9) DNA positivity and mean 
DNA viral load in transplant patients over time, the Netherlands. 
Bars indicate percentage of HPyV9-positive patients; line indicates 
DNA load. Time points are shown as described in Table 2. Pre, 
pretransplant (baseline).
HPyV9 in Kidney Transplant Patients
in kidney–pancreas transplant patients was confirmed by 
analyzing the complete dataset with a mixed model analy-
sis (p = 0.003; data not shown).
No Correlation between HPyV9 Viremia  
and Seroreactivity
Because HPyV9 DNA detection and seroresponses 
increased after transplantation, we investigated the correla-
tion between these parameters. Comparable proportions of 
patients who were HPyV9-seropositive and -seronegative 
at baseline became HPyV9 DNA-positive during follow-up 
(6/35 [17%] and 15/66 [23%], respectively; p = 0.510 by χ2 
test) (Figure 3, panel A), and the measured mean viral loads 
were comparable for the 2 groups (169 and 152 copies/mL, 
respectively; p = 0.798 by Student t test). Furthermore, we 
analyzed whether the presence of HPyV9 DNA influenced 
HPyV9 seroreactivity during follow up and found no as-
sociation (Figure 3, panel B); we also found no association 
when we compared HPyV9 DNA positivity between high 
and low seroresponders (above and below median MFI) and 
seroconverters (data not shown). Stratified analyses for kid-
ney–pancreas and kidney transplant patients did not alter the 
lack of association. HPyV9 DNA and seroreactivity profiles 
for patients who seroconverted and/or became viremic dur-
ing follow-up are shown in the online Technical Appendix.
Correlation between HPyV9 and BKPyV Viremia
Of 541 samples tested, 225 (42%) were BKPyV DNA 
positive; these samples came from 86 (85%) of the 101 
transplant patients. HPyV9 DNA was detected significantly 
more frequently in BKPyV DNA–positive samples than in 
BKPyV DNA–negative samples (9.8% vs. 1.6%, respec-
tively; p<0.001 by χ2 test) (Figure 4, panel A). During 
follow-up, HPyV9 DNA was more often detected in BK-
PyV DNA–positive patients than in BKPyV-negative pa-
tients (23.3% vs. 6.7%%, respectively; p = 0.185 by Fisher 
exact test) (Figure 4, panel B). Furthermore, we divided 
BKPyV viremic patients into 2 groups, those with high 
(>103 copies/mL) and low (<103 copies/mL) BKPyV DNA 
loads, and found HPyV9 DNA–positive patients were 
overrepresented among patients with high BKPyV loads (p 
= 0.001 by Fisher exact test; Figure 4, panel C). For 11 
(55%) of 20 co-infected patients, BKPyV viremia coin-
cided with HPyV9 viremia; for 8 (40%), BKPyV viremia 
preceded HPyV9 viremia.
We additionally assessed the presence of viremia 
caused by CMV, a herpes virus that is not phylogenetically 
related to HPyV9 and not particularly related to urinary tract 
infections but that frequently reactivates during immuno-
suppressive drug use after transplantation. CMV DNA was 
detected at some point after transplantation in 27 (27%) 
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Figure 2. Human polyomavirus 
9 (HPyV9) seropositivity and 
seroreactivity in samples from 
transplant patients and healthy 
blood donor controls collected 
1 year apart, the Netherlands. 
Black bars, baseline samples; 
white bars, follow-up samples 
(Table 2). Values below 
bars indicate no. persons 
positive/total no. tested. A) 
Seropositivity percentages for 
transplant patients and controls; 
B) seroreactivity levels for 
transplant patients and controls; 
C) seropositivity percentages for 
kidney transplant and kidney–
pancreas transplant patients; D) 
seroreactivity levels for kidney 
transplant and kidney–pancreas 
transplant patients. MFI, median 




of the 101 patients (43 [8%] of 541 tested samples). The 
proportion of HPyV9 DNA–positive samples was similar 
among CMV DNA positive and negative samples (7% and 
5%, respectively; Figure 4, panel A), and no associations 
were found when comparing HPyV9 DNA positivity and 
seropositivity among patients who were negative or posi-
tive for CMV DNA (Figure 4, panel B; data not shown).
Discussion
We systematically assessed the presence of HPyV9 
DNA and IgG responses in posttransplantation serum sam-
ples from kidney transplant patients. These markers of vi-
remia and seroreactivity were shown to increase after trans-
plantation, indicative of active HPyV9 infection, whereas 
the levels remained stable in matched healthy blood donors.
HPyV9 viremia was detected in 21% of transplant 
patients at some point within 18 months after transplan-
tation. Most patients were viremic at a single time point, 
predominantly 3 months after transplantation. The highest 
mean viral loads were observed immediately after trans-
plantation and decreased gradually over time, but overall 
HPyV9 loads were low (25–530 copies/mL). Repeat analy-
sis of the complete sample set of 541 serum samples re-
confirmed HPyV9 viremia in the same patients (data not 
shown). At the same time, reanalysis of our cohort showed 
that the time of a positive finding sometimes differed with-
in viremic patients, compatible with the idea that the viral 
loads are generally low in persons with HPyV9 viremia and 
sometimes fall below the PCR detection limit.
Since the identification of HPyV9 in 2011 (17), one 
study has reported detection of the virus in blood from 2% 
of immunosuppressed patients (31), whereas other studies 
did not find HPyV9 (32,33). These studies did not report 
the time of sampling in relation to transplantation and im-
munosuppression. Our data suggest that active HPyV9 
infection is particularly found in the first year after trans-
plantation. After 18 months, only 2.5% of our transplant 
patients were HPyV9 DNA–positive, with a mean viral 
load of 51 copies/mL. The use of different primer sets (and 
probes) in different studies, with different specificity and 
sensitivity for the detection of HPyV9 DNA, hampers an 
accurate comparison among studies.
We observed a peak in HPyV9 DNA detection and 
load in the first 3 months after transplantation, which coin-
cides with the highest dose of immunosuppressive medica-
tion administered to these patients. HPyV9 DNA was not 
detected in serum samples from patients before transplanta-
tion or in serum samples from healthy blood donors. Taken 
together, these observations indicate a close relationship 
between active HPyV9 infection and transplantation and/
or immunosuppression. The higher mean viral load de-
tected in patients who received a combined kidney–pan-
creas transplant might be the result of the more intensified 
immunosuppressive regime applied to these patients. Al-
ternatively, the underlying cause of kidney failure might 
predispose patients for more frequent HPyV9 infection: 
94% of kidney–pancreas transplant patients had diabetes, 
compared with only 6% of kidney transplant patients.
During follow-up, HPyV9 seroprevalence signifi-
cantly increased among transplant patients, from 33% to 
46%, but remained stable at ≈30% in a control group of 
healthy blood donors among whom no HPyV9 DNA was 
detected. A previous cross-sectional study observed a 
comparable difference in HPyV9 seroprevalence between 
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Figure 3. Kaplan-Meier curves showing proportional increase of 
human polyomavirus 9 (HPyV9) DNA–positive and seropositive 
transplant patients during 12-month follow-up, the Netherlands. A) 
Cumulative HPyV9 DNA positivity (viremia) for transplant patients 
who were seronegative (gray) or seropositive (black) at baseline. 
B) Cumulative HPyV9 seropositivity for transplant patients who 
were nonviremic (gray) or viremic (black) at baseline.
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kidney transplant patients (65%) and healthy persons 
(45%) (25).
The detection of HPyV9 DNA and the increase in 
HPyV9 seroreactivity observed after transplantation could 
reflect primary infection and reactivation. Polyomavirus 
infections after transplantation and immunosuppression 
could result from endogenous reactivation, but proof of 
this concept is lacking. Infection/reactivation originating 
from the transplanted organ, as suggested for BKPyV (34), 
should be considered in the case of HPyV9, especially be-
cause HPyV9 viremia and baseline HPyV9 seroreactivity 
were not correlated in this study. HPyV9 viremia was fre-
quently detected in baseline samples from seronegative 
transplant patients, which suggests donor-derived infection 
rather than endogenous reactivation. 
Additional analysis of our findings showed that 
HPyV9 viremia was more prevalent in BKPyV DNA–
positive samples and in BKPyV-viremic patients than in 
their BKPyV DNA–negative equivalents; this association 
reached statistical significance in BKPyV DNA–positive 
samples. Stratified analysis revealed that HPyV9 DNA 
positivity was correlated with high BKPyV load. Taken 
together, these observations suggest that these related vi-
ruses benefit from a joint risk factor present in immuno-
suppressed kidney transplant patients. The observation that 
CMV and HPyV9 viremia were not associated, however, 
suggests that the joint risk factor for the polyomaviruses 
is not simply explained by immunosuppression, which is a 
well-known risk factor for CMV.
Although we provide strong evidence for emergence 
of HPyV9 infection in kidney transplant patients and for as-
sociation between HPyV9 and BKPyV infection, this study 
has its limitations. The cohort of kidney transplantation pa-
tients we tested was small (n = 101) and was formed >10 
years ago. Confirmation of our observations in a more recent 
and larger cohort will strengthen our findings. Because we 
were not able to investigate whether donor HPyV9 serosta-
tus correlated with HPyV9 viremia in the recipient, future 
research might explore the possibility of the donor organ as 
the source of HPyV9 infection. Furthermore, studies that in-
clude urine samples that were not available for our analyses 
could investigate urinary excretion of HPyV9 in the infected 
patients and might confirm the epidemiologic correlations 
we found in serum samples. Finally, the sensitivity of de-
tecting HPyV9 viremic episodes was limited by the 3-month 
sampling interval. Future studies using a shorter sampling 
interval would increase the number of measurements.
In conclusion, we identified HPyV9 as an emerg-
ing infection in immunosuppressed kidney transplant pa-
tients. The observed prevalence of HPyV9 DNA in serum 
samples (21%) considerably exceeded detection rates of 
HPyV9 found by others in skin samples of immunocompe-
tent (0.9%) and immuncompromised (2.0%) persons (35), 
which suggests that HPyV9 causes systemic rather than 
skin infection. Whether HPyV9 is pathogenic in immuno-
compromised patients, alone or in concert with the well-
known pathogen BKPyV, deserves further study. In this 
context, it would be worthwhile to investigate the course of 
BKPyV viremia and development of BK virus–associated 
nephropathy in HPyV9-positive and -negative patients.
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bars) and viremic (gray bars) patients; C) percentage of HPyV9 DNA–positive samples by measured BKPyV load within the same sample: 
low, <103 copies/mL (white bars) or high, >103 copies/mL (black bars). Values below bars indicate no. persons positive/total no. tested. 
*Significant (p<0.05 by χ2 test).
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